Global Chronic Kidney Disease (CKD) Drugs Market 2024-2028

The chronic kidney disease (CKD) drugs market is forecasted to grow by USD 3.81 bn during 2023-2028, accelerating at a CAGR of 4.77% during the forecast period. The report on the chronic kidney disease (CKD) drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of CKD globally, increase in healthcare expenditure globally, and growing awareness about need for early detection and diagnosis of CKD.

Market Scope
Base Year	2023
End Year	2028
Series Year	2024-2028
Growth Momentum	Accelerate
YOY 2024	4.57%
CAGR	4.77%
Incremental Value	$3.81bn

Technavio's chronic kidney disease (CKD) drugs market is segmented as below:

By Drug Class

Erythropoietin stimulating agents
Calcium channel blockers
Phosphate binders
ACE inhibitors
Others

By Route Of Administration

Oral
Subcutaneous
Intravenous

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the growing number of drug approvals for CKD treatment as one of the prime reasons driving the chronic kidney disease (CKD) drugs market growth during the next few years. Also, rising focus on adoption of precision medicine for CKD treatment and technological innovations in CKD treatment will lead to sizable demand in the market.

The report on the chronic kidney disease (CKD) drugs market covers the following areas:

Chronic kidney disease (CKD) drugs market sizing
Chronic kidney disease (CKD) drugs market forecast
Chronic kidney disease (CKD) drugs market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading chronic kidney disease (CKD) drugs market vendors that include Abbott Laboratories, AbbVie Inc., Akebia Therapeutics Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Cara Therapeutics Inc., Eli Lilly and Co., F. Hoffmann La Roche Ltd., FibroGen Inc., Horizon Therapeutics Plc, Johnson and Johnson, Kissei Pharmaceutical Co. Ltd., Novartis AG, OPKO Health Inc., Pfizer Inc., Pharmacosmos AS, Rockwell Medical Inc., Sanofi SA, Shield Therapeutics plc, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Xenetic Biosciences Inc., Zydus Lifesciences Ltd., Ardelyx Inc., and Aurinia Pharmaceuticals Inc.. Also, the chronic kidney disease (CKD) drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Product Code: IRTNTR76853

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibit 06: Executive Summary - Chart on Market Segmentation by Route of Administration
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global chronic kidney disease (CKD) drugs market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global chronic kidney disease (ckd) drugs market 2018 - 2022 ($ billion)
4.2 Drug Class Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Drug Class Segment 2018 - 2022 ($ billion)
4.3 Route of Administration Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Route of Administration Segment 2018 - 2022 ($ billion)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Drug Class

6.1 Market segments
Exhibit 30: Chart on Drug Class - Market share 2023-2028 (%)
Exhibit 31: Data Table on Drug Class - Market share 2023-2028 (%)
6.2 Comparison by Drug Class
Exhibit 32: Chart on Comparison by Drug Class
Exhibit 33: Data Table on Comparison by Drug Class
6.3 Erythropoietin stimulating agents (ESAs) - Market size and forecast 2023-2028
Exhibit 34: Chart on Erythropoietin stimulating agents (ESAs) - Market size and forecast 2023-2028 ($ billion)
Exhibit 35: Data Table on Erythropoietin stimulating agents (ESAs) - Market size and forecast 2023-2028 ($ billion)
Exhibit 36: Chart on Erythropoietin stimulating agents (ESAs) - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Erythropoietin stimulating agents (ESAs) - Year-over-year growth 2023-2028 (%)
6.4 Calcium channel blockers - Market size and forecast 2023-2028
Exhibit 38: Chart on Calcium channel blockers - Market size and forecast 2023-2028 ($ billion)
Exhibit 39: Data Table on Calcium channel blockers - Market size and forecast 2023-2028 ($ billion)
Exhibit 40: Chart on Calcium channel blockers - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Calcium channel blockers - Year-over-year growth 2023-2028 (%)
6.5 Phosphate binders - Market size and forecast 2023-2028
Exhibit 42: Chart on Phosphate binders - Market size and forecast 2023-2028 ($ billion)
Exhibit 43: Data Table on Phosphate binders - Market size and forecast 2023-2028 ($ billion)
Exhibit 44: Chart on Phosphate binders - Year-over-year growth 2023-2028 (%)
Exhibit 45: Data Table on Phosphate binders - Year-over-year growth 2023-2028 (%)
6.6 ACE inhibitors - Market size and forecast 2023-2028
Exhibit 46: Chart on ACE inhibitors - Market size and forecast 2023-2028 ($ billion)
Exhibit 47: Data Table on ACE inhibitors - Market size and forecast 2023-2028 ($ billion)
Exhibit 48: Chart on ACE inhibitors - Year-over-year growth 2023-2028 (%)
Exhibit 49: Data Table on ACE inhibitors - Year-over-year growth 2023-2028 (%)
6.7 Others - Market size and forecast 2023-2028
Exhibit 50: Chart on Others - Market size and forecast 2023-2028 ($ billion)
Exhibit 51: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
Exhibit 52: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibit 53: Data Table on Others - Year-over-year growth 2023-2028 (%)
6.8 Market opportunity by Drug Class
Exhibit 54: Market opportunity by Drug Class ($ billion)
Exhibit 55: Data Table on Market opportunity by Drug Class ($ billion)

7 Market Segmentation by Route of Administration

7.1 Market segments
Exhibit 56: Chart on Route of Administration - Market share 2023-2028 (%)
Exhibit 57: Data Table on Route of Administration - Market share 2023-2028 (%)
7.2 Comparison by Route of Administration
Exhibit 58: Chart on Comparison by Route of Administration
Exhibit 59: Data Table on Comparison by Route of Administration
7.3 Oral - Market size and forecast 2023-2028
Exhibit 60: Chart on Oral - Market size and forecast 2023-2028 ($ billion)
Exhibit 61: Data Table on Oral - Market size and forecast 2023-2028 ($ billion)
Exhibit 62: Chart on Oral - Year-over-year growth 2023-2028 (%)
Exhibit 63: Data Table on Oral - Year-over-year growth 2023-2028 (%)
7.4 Subcutaneous - Market size and forecast 2023-2028
Exhibit 64: Chart on Subcutaneous - Market size and forecast 2023-2028 ($ billion)
Exhibit 65: Data Table on Subcutaneous - Market size and forecast 2023-2028 ($ billion)
Exhibit 66: Chart on Subcutaneous - Year-over-year growth 2023-2028 (%)
Exhibit 67: Data Table on Subcutaneous - Year-over-year growth 2023-2028 (%)
7.5 Intravenous - Market size and forecast 2023-2028
Exhibit 68: Chart on Intravenous - Market size and forecast 2023-2028 ($ billion)
Exhibit 69: Data Table on Intravenous - Market size and forecast 2023-2028 ($ billion)
Exhibit 70: Chart on Intravenous - Year-over-year growth 2023-2028 (%)
Exhibit 71: Data Table on Intravenous - Year-over-year growth 2023-2028 (%)
7.6 Market opportunity by Route of Administration
Exhibit 72: Market opportunity by Route of Administration ($ billion)
Exhibit 73: Data Table on Market opportunity by Route of Administration ($ billion)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 74: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 75: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 76: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 77: Chart on Geographic comparison
Exhibit 78: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 79: Chart on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 80: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 81: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 83: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 84: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 85: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 87: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 88: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 89: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 91: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 92: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 93: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 95: Chart on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 96: Data Table on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 97: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 China - Market size and forecast 2023-2028
Exhibit 99: Chart on China - Market size and forecast 2023-2028 ($ billion)
Exhibit 100: Data Table on China - Market size and forecast 2023-2028 ($ billion)
Exhibit 101: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on China - Year-over-year growth 2023-2028 (%)
9.9 Germany - Market size and forecast 2023-2028
Exhibit 103: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 104: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 105: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 106: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.10 UK - Market size and forecast 2023-2028
Exhibit 107: Chart on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 108: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 109: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 110: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.11 India - Market size and forecast 2023-2028
Exhibit 111: Chart on India - Market size and forecast 2023-2028 ($ billion)
Exhibit 112: Data Table on India - Market size and forecast 2023-2028 ($ billion)
Exhibit 113: Chart on India - Year-over-year growth 2023-2028 (%)
Exhibit 114: Data Table on India - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 115: Market opportunity By Geographical Landscape ($ billion)
Exhibit 116: Data Tables on Market opportunity By Geographical Landscape ($ billion)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 117: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 118: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 119: Overview on factors of disruption
11.4 Industry risks
Exhibit 120: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 121: Vendors covered
12.2 Market positioning of vendors
Exhibit 122: Matrix on vendor position and classification
12.3 Abbott Laboratories
Exhibit 123: Abbott Laboratories - Overview
Exhibit 124: Abbott Laboratories - Business segments
Exhibit 125: Abbott Laboratories - Key news
Exhibit 126: Abbott Laboratories - Key offerings
Exhibit 127: Abbott Laboratories - Segment focus
12.4 AbbVie Inc.
Exhibit 128: AbbVie Inc. - Overview
Exhibit 129: AbbVie Inc. - Product / Service
Exhibit 130: AbbVie Inc. - Key news
Exhibit 131: AbbVie Inc. - Key offerings
12.5 Amgen Inc.
Exhibit 132: Amgen Inc. - Overview
Exhibit 133: Amgen Inc. - Product / Service
Exhibit 134: Amgen Inc. - Key offerings
12.6 AstraZeneca Plc
Exhibit 135: AstraZeneca Plc - Overview
Exhibit 136: AstraZeneca Plc - Product / Service
Exhibit 137: AstraZeneca Plc - Key news
Exhibit 138: AstraZeneca Plc - Key offerings
12.7 Bayer AG
Exhibit 139: Bayer AG - Overview
Exhibit 140: Bayer AG - Business segments
Exhibit 141: Bayer AG - Key news
Exhibit 142: Bayer AG - Key offerings
Exhibit 143: Bayer AG - Segment focus
12.8 Biogen Inc.
Exhibit 144: Biogen Inc. - Overview
Exhibit 145: Biogen Inc. - Product / Service
Exhibit 146: Biogen Inc. - Key offerings
12.9 Boehringer Ingelheim International GmbH
Exhibit 147: Boehringer Ingelheim International GmbH - Overview
Exhibit 148: Boehringer Ingelheim International GmbH - Business segments
Exhibit 149: Boehringer Ingelheim International GmbH - Key news
Exhibit 150: Boehringer Ingelheim International GmbH - Key offerings
Exhibit 151: Boehringer Ingelheim International GmbH - Segment focus
12.10 Eli Lilly and Co.
Exhibit 152: Eli Lilly and Co. - Overview
Exhibit 153: Eli Lilly and Co. - Product / Service
Exhibit 154: Eli Lilly and Co. - Key news
Exhibit 155: Eli Lilly and Co. - Key offerings
12.11 F. Hoffmann La Roche Ltd.
Exhibit 156: F. Hoffmann La Roche Ltd. - Overview
Exhibit 157: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 158: F. Hoffmann La Roche Ltd. - Key news
Exhibit 159: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 160: F. Hoffmann La Roche Ltd. - Segment focus
12.12 Horizon Therapeutics Plc
Exhibit 161: Horizon Therapeutics Plc - Overview
Exhibit 162: Horizon Therapeutics Plc - Business segments
Exhibit 163: Horizon Therapeutics Plc - Key news
Exhibit 164: Horizon Therapeutics Plc - Key offerings
Exhibit 165: Horizon Therapeutics Plc - Segment focus
12.13 Johnson and Johnson
Exhibit 166: Johnson and Johnson - Overview
Exhibit 167: Johnson and Johnson - Business segments
Exhibit 168: Johnson and Johnson - Key news
Exhibit 169: Johnson and Johnson - Key offerings
Exhibit 170: Johnson and Johnson - Segment focus
12.14 Novartis AG
Exhibit 171: Novartis AG - Overview
Exhibit 172: Novartis AG - Business segments
Exhibit 173: Novartis AG - Key offerings
Exhibit 174: Novartis AG - Segment focus
12.15 OPKO Health Inc.
Exhibit 175: OPKO Health Inc. - Overview
Exhibit 176: OPKO Health Inc. - Business segments
Exhibit 177: OPKO Health Inc. - Key offerings
Exhibit 178: OPKO Health Inc. - Segment focus
12.16 Pfizer Inc.
Exhibit 179: Pfizer Inc. - Overview
Exhibit 180: Pfizer Inc. - Product / Service
Exhibit 181: Pfizer Inc. - Key news
Exhibit 182: Pfizer Inc. - Key offerings
12.17 Sanofi SA
Exhibit 183: Sanofi SA - Overview
Exhibit 184: Sanofi SA - Business segments
Exhibit 185: Sanofi SA - Key news
Exhibit 186: Sanofi SA - Key offerings
Exhibit 187: Sanofi SA - Segment focus

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 188: Inclusions checklist
Exhibit 189: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 190: Currency conversion rates for US$
13.4 Research methodology
Exhibit 191: Research methodology
Exhibit 192: Validation techniques employed for market sizing
Exhibit 193: Information sources
13.5 List of abbreviations
Exhibit 194: List of abbreviations